Profile data is unavailable for this security.
About the company
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.
- Revenue in USD (TTM)1.24bn
- Net income in USD23.68m
- Incorporated2015
- Employees2.90k
- LocationLivaNova PLC20 Eastbourne TerraceLONDON W2 6LGUnited KingdomGBR
- Phone+44 203 325 0662
- Websitehttps://www.livanova.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novocure Ltd | 577.74m | -149.78m | 1.92bn | 1.45k | -- | 5.63 | -- | 3.32 | -1.39 | -1.39 | 5.37 | 3.34 | 0.4879 | 3.59 | 8.74 | 397,617.30 | -12.65 | -7.74 | -20.29 | -8.95 | 76.42 | 77.22 | -25.93 | -14.69 | 1.44 | -- | 0.6446 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
| Tandem Diabetes Care Inc | 854.35m | -126.78m | 2.02bn | 2.40k | -- | 8.40 | -- | 2.37 | -1.94 | -1.94 | 13.08 | 3.62 | 0.9004 | 2.90 | 8.23 | 355,979.60 | -13.36 | -10.08 | -17.47 | -12.23 | 49.79 | 51.77 | -14.84 | -11.59 | 2.32 | -- | 0.5945 | -- | -6.68 | 32.39 | -135.33 | -- | 76.81 | -- |
| Omnicell Inc | 1.06bn | -17.69m | 2.12bn | 3.66k | -- | 1.73 | 31.88 | 1.99 | -0.3917 | -0.3917 | 23.17 | 26.59 | 0.4704 | 5.90 | 4.06 | 291,563.30 | -0.7817 | 1.73 | -1.11 | 2.25 | 41.44 | 46.69 | -1.66 | 2.92 | 0.9529 | -- | 0.3172 | 0.00 | -11.48 | 7.82 | -460.68 | -- | 0.235 | -- |
| Premier Inc | 1.28bn | 147.17m | 2.20bn | 2.90k | 16.76 | 1.16 | 8.36 | 1.72 | 1.38 | 1.37 | 11.65 | 19.98 | 0.3562 | -- | 2.99 | 439,914.10 | 3.83 | 7.08 | 4.78 | 8.95 | 67.24 | 61.29 | 10.76 | 16.05 | -- | -- | 0.2771 | 27.32 | 0.7684 | 2.03 | -31.70 | -11.93 | -2.76 | -- |
| Conmed Corp | 1.29bn | 131.74m | 2.31bn | 4.00k | 18.34 | 2.57 | 11.37 | 1.80 | 4.23 | 4.23 | 41.38 | 30.21 | 0.555 | 1.71 | 5.58 | 322,029.00 | 5.68 | 0.8972 | 6.62 | 1.02 | 55.65 | 54.95 | 10.23 | 1.65 | 1.06 | 5.22 | 0.5021 | 139.16 | 19.06 | 7.68 | 179.99 | 10.04 | 2.89 | 0.00 |
| Irhythm Technologies Inc | 560.03m | -150.66m | 2.32bn | 2.00k | -- | 35.89 | -- | 4.14 | -4.85 | -4.85 | 18.04 | 2.29 | 0.83 | 12.56 | 8.79 | 280,012.50 | -22.33 | -21.92 | -26.27 | -26.77 | 67.83 | 69.39 | -26.90 | -25.75 | 6.12 | -24.18 | 0.90 | -- | 19.90 | 27.32 | -6.24 | -- | 50.82 | -- |
| UFP Technologies Inc | 461.85m | 54.21m | 2.39bn | 3.09k | 44.92 | 7.33 | 35.53 | 5.17 | 7.00 | 7.00 | 59.64 | 42.89 | 0.8896 | 4.18 | 6.15 | 149,320.40 | 10.44 | 9.69 | 12.00 | 10.95 | 28.31 | 26.33 | 11.74 | 10.14 | 1.43 | 13.44 | 0.3919 | 0.00 | 13.08 | 16.00 | 7.50 | 25.71 | 14.08 | -- |
| LeMaitre Vascular Inc | 213.03m | 41.32m | 2.43bn | 614.00 | 58.74 | 7.27 | 47.64 | 11.40 | 1.82 | 1.82 | 9.41 | 14.73 | 0.5992 | 1.11 | 7.59 | 346,952.80 | 11.62 | 9.02 | 12.66 | 9.93 | 68.34 | 65.83 | 19.40 | 15.45 | 5.52 | -- | 0.00 | 40.41 | 19.69 | 12.88 | 45.89 | 5.96 | 18.93 | 15.51 |
| TransMedics Group Inc | 401.09m | 32.64m | 2.55bn | 584.00 | 83.69 | 12.56 | 50.59 | 6.36 | 0.9389 | 0.9389 | 11.60 | 6.25 | 0.5439 | 3.56 | 5.32 | 686,797.90 | 4.43 | -16.08 | 4.78 | -17.95 | 59.34 | 65.37 | 8.14 | -40.47 | 7.33 | -- | 0.7078 | -- | 158.53 | 79.36 | 30.92 | -- | 225.12 | -- |
| Enovis Corp | 2.00bn | -121.38m | 2.61bn | 6.55k | -- | 0.8097 | 17.83 | 1.30 | -2.21 | -2.17 | 36.43 | 59.61 | 0.4023 | 1.59 | 5.91 | 305,598.20 | -2.43 | -0.3569 | -2.66 | -0.41 | 56.96 | 48.19 | -6.03 | -1.06 | 1.12 | 0.9889 | 0.2876 | -- | 9.22 | -4.89 | -40.29 | -- | 11.91 | -- |
| Quidelortho Corp | 2.82bn | -1.87bn | 2.70bn | 7.10k | -- | 0.868 | -- | 0.9581 | -27.89 | -27.89 | 42.04 | 47.42 | 0.3674 | 2.62 | 7.84 | 396,859.20 | -24.34 | 11.34 | -27.75 | 12.91 | 47.62 | 62.71 | -66.25 | 20.93 | 0.8134 | 0.7419 | 0.4446 | 0.00 | -8.21 | 41.83 | -101.84 | -- | 45.87 | -- |
| Warby Parker Inc | 742.53m | -32.56m | 2.78bn | 2.14k | -- | 8.59 | 245.17 | 3.75 | -0.2731 | -0.2731 | 6.20 | 2.80 | 1.22 | 5.70 | 818.21 | 346,975.20 | -5.37 | -- | -6.78 | -- | 55.32 | 57.49 | -4.39 | -14.53 | 2.06 | -- | 0.00 | -- | 11.98 | 19.67 | 42.75 | -- | -- | -- |
| LivaNova PLC | 1.24bn | 23.68m | 2.79bn | 2.90k | 121.50 | 2.14 | 41.07 | 2.24 | 0.4259 | 0.4259 | 22.81 | 24.13 | 0.5119 | 2.47 | 6.42 | 428,185.90 | 0.9777 | -6.01 | 1.12 | -7.42 | 67.78 | 66.99 | 1.91 | -13.56 | 2.87 | 2.46 | 0.3234 | -- | 12.89 | 0.8278 | 120.34 | -- | -1.64 | -- |
| Inari Medical Inc | 574.50m | -78.58m | 2.91bn | 1.30k | -- | 6.65 | -- | 5.06 | -1.35 | -1.35 | 9.90 | 7.44 | 0.9221 | 1.59 | 7.46 | 441,921.50 | -12.61 | -0.5941 | -15.24 | -0.6696 | 86.82 | 89.06 | -13.68 | -0.6295 | 1.40 | -- | 0.00 | -- | 28.73 | 135.40 | 94.41 | -- | 52.46 | -- |
| Neogen Corp | 912.20m | -23.53m | 3.25bn | 2.92k | -- | 1.06 | 34.44 | 3.56 | -0.1086 | -0.1086 | 4.21 | 14.47 | 0.2013 | 2.71 | 5.98 | 312,718.20 | -0.5193 | 1.38 | -0.5346 | 1.44 | 49.56 | 48.23 | -2.58 | 4.31 | 2.79 | 1.03 | 0.2215 | 0.00 | 12.37 | 17.41 | 58.81 | -- | 50.02 | -- |
| Envista Holdings Corp | 2.50bn | -1.34bn | 3.70bn | 12.80k | -- | 1.24 | -- | 1.48 | -7.77 | -7.77 | 14.51 | 17.86 | 0.4106 | 4.21 | 6.19 | 195,570.30 | -21.93 | 1.94 | -25.27 | 2.34 | 54.20 | 57.65 | -53.42 | 5.29 | 1.77 | 3.13 | 0.3163 | 0.00 | -0.1012 | -2.04 | -142.10 | -- | -4.22 | -- |
Data as of Nov 25 2024. Currency figures normalised to LivaNova PLC's reporting currency: US Dollar USD
48.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2024 | 6.38m | 11.74% |
| PRIMECAP Management Co.as of 30 Sep 2024 | 5.63m | 10.37% |
| Millennium Management LLCas of 30 Sep 2024 | 2.96m | 5.45% |
| Point72 Asset Management LPas of 30 Sep 2024 | 2.27m | 4.19% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 2.04m | 3.76% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.98m | 3.65% |
| Capital Research & Management Co. (Global Investors)as of 30 Sep 2024 | 1.35m | 2.49% |
| Geode Capital Management LLCas of 30 Sep 2024 | 1.34m | 2.48% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 1.10m | 2.02% |
| P2 Capital Partners LLCas of 30 Sep 2024 | 1.05m | 1.93% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
